Peng Huang, Ph.D.
Project Involvement: Project 5 - Novel Pharmacologic Agents in CLL
Our laboratory research are in the areas of metabolic alterations in cancer cells and mechanisms of action of novel anticancer agents. The goals our research programs are to investigate the fundamental changes in energy metabolism and redox regulation in cancer, to examine the molecular interaction between the cancer cells and anticancer drugs, and to develop novel strategies to selectively kill the malignant T-cells based on their metabolic alterations and survival pathways. Current research efforts are directed toward investigating the role of mitochondria in affecting glycolysis and drug-induced apoptosis, and examining the effect of oncogenic signals on mitochondrial respiration and ROS generation. Another important focus is the role of p53 and its associated molecules in sensing DNA damage by reactive oxygen species (ROS) and other genotoxic agents and the subsequent signaling for apoptosis. The understanding of the difference between the cancer cells and normal cells in their ATP metabolism and ROS/redox regulation will provide an important basis for developing novel agents and new strategies to selectively kill cancer cells and improve therapeutic activity and selectivity for cancer treatment.
Education & Training
1990 – The University of Texas Health Science Center at Houston, Graduate School of Biomedical Sciences, Houston, TX, PhD, Pharmacology
1982 – Zhongshan Medical College, Guangzhou, China, MD, Medicine
6/1990-11/1992– Postdoctoral Fellow, Department of Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX
1/1983-8/1984 – Postgraduate Fellowship, Department of Clinical Pharmacology, Sun Yat-Sen University of Medical Sciences, Guangzhou, China